| Bodybuilding.com | 77.2 | 2 | 1 |
| Joseph E. Stiglitz | 60.0 | 2 | 0 |
| Target Corporation | 60.0 | 2 | 0 |
| FreshDirect | 60.0 | 2 | 0 |
| Yahoo! Finance | 60.0 | 2 | 0 |
| Center for Drug Evaluation and Research | 60.0 | 2 | 0 |
| Trustpilot | 60.0 | 2 | 0 |
| Forbes 30 Under 30 | 60.0 | 2 | 0 |
| Forbes ASAP | 60.0 | 2 | 0 |
| Forbes Best-In-State Wealth Advisor | 60.0 | 2 | 0 |
| Forbes Top 250 Wealth Advisor | 60.0 | 2 | 0 |
| GNC | 55.1 | 1 | 1 |
| The Vitamin Shoppe | 55.1 | 1 | 1 |
| Labdoor, Inc | 55.1 | 1 | 1 |
| Super Supplements | 55.1 | 1 | 1 |
| Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial | 40.0 | 0 | 4 |
| Kroger | 37.9 | 1 | 0 |
| United States Food and Drug Administration | 37.9 | 1 | 0 |
| Q483551 | 37.9 | 1 | 0 |
| The World's Billionaires | 37.9 | 1 | 0 |
| Costco | 37.9 | 1 | 0 |
| Columbia Business School | 37.9 | 1 | 0 |
| Forbes | 37.9 | 1 | 0 |
| The World's Most Powerful People | 37.9 | 1 | 0 |
| Forbes Global 2000 | 37.9 | 1 | 0 |
| Mike Lazaridis | 37.9 | 1 | 0 |
| Walgreens | 37.9 | 1 | 0 |
| Ritual Entertainment | 37.9 | 1 | 0 |
| Whole Foods Market | 37.9 | 1 | 0 |
| CVS Pharmacy | 37.9 | 1 | 0 |
| Forbes 400 | 37.9 | 1 | 0 |
| Price Club | 37.9 | 1 | 0 |
| Nature's Sunshine Products | 37.9 | 1 | 0 |
| AOL Seed | 37.9 | 1 | 0 |
| ArrayTrack | 37.9 | 1 | 0 |
| Bad Bug Book | 37.9 | 1 | 0 |
| Center for Biologics Evaluation and Research | 37.9 | 1 | 0 |
| Center for Devices and Radiological Health | 37.9 | 1 | 0 |
| Center for Food Safety and Applied Nutrition | 37.9 | 1 | 0 |
| Center for Tobacco Products | 37.9 | 1 | 0 |
| Center for Veterinary Medicine | 37.9 | 1 | 0 |
| ConsumerAffairs.com | 37.9 | 1 | 0 |
| ConsumerLab.com | 37.9 | 1 | 0 |
| Earth Fare | 37.9 | 1 | 0 |
| Enfamil | 37.9 | 1 | 0 |
| Matka gambling | 37.9 | 1 | 0 |
| National Center for Toxicological Research | 37.9 | 1 | 0 |
| Office of Criminal Investigations | 37.9 | 1 | 0 |
| Regional Centre for Biotechnology | 37.9 | 1 | 0 |
| Sprouts Farmers Market | 37.9 | 1 | 0 |
| Swanson Health Products | 37.9 | 1 | 0 |
| Vitacost | 37.9 | 1 | 0 |
| Vitamin World | 37.9 | 1 | 0 |
| Forbes' list of the world's highest-paid athletes | 37.9 | 1 | 0 |
| Mohamed Mansour | 37.9 | 1 | 0 |
| list of Walmart brands | 37.9 | 1 | 0 |
| Healthline | 37.9 | 1 | 0 |
| Mountain Rose Herbs | 37.9 | 1 | 0 |
| Natural Grocers | 37.9 | 1 | 0 |
| Murder Kroger | 37.9 | 1 | 0 |
| Thorlabs | 37.9 | 1 | 0 |
| Joseph John Klimek | 37.9 | 1 | 0 |
| Forbes | 37.9 | 1 | 0 |
| Thrive Market | 37.9 | 1 | 0 |
| FDA medical bulletin : important information for health professionals from the U.S. Food & Drug Administration | 37.9 | 1 | 0 |
| Well.ca | 37.9 | 1 | 0 |
| Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome | 34.5 | 0 | 3 |
| Dietary fiber, food intolerance, and irritable bowel syndrome | 34.5 | 0 | 3 |
| Influence of Dietary Fiber in Low FODMAP Diet for Irritable Bowel Syndrome | 34.5 | 0 | 3 |
| Effects of Low FODMAP Diet on Leaky Gut | 34.5 | 0 | 3 |
| Saccharomyces boulardii CNCM I-745 modulates the microbiota-gut-brain axis in a humanized mouse model of Irritable Bowel Syndrome | 34.5 | 0 | 3 |
| Vitaminstore | 34.5 | 0 | 3 |
| Q134608388 | 34.5 | 0 | 3 |
| multivitamin | 27.3 | 0 | 2 |
| digestive enzyme | 27.3 | 0 | 2 |
| dietary supplement | 27.3 | 0 | 2 |
| synbiotics | 27.3 | 0 | 2 |
| Dietary Supplements | 27.3 | 0 | 2 |
| Journal of Dietary Supplements | 27.3 | 0 | 2 |
| Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes | 27.3 | 0 | 2 |
| Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date | 27.3 | 0 | 2 |
| Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health? | 27.3 | 0 | 2 |
| Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome | 27.3 | 0 | 2 |
| Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future | 27.3 | 0 | 2 |
| Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study | 27.3 | 0 | 2 |
| A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life | 27.3 | 0 | 2 |
| Reversal of Irritable Bowel Syndrome, Sleep Disturbance, and Fatigue With an Elimination Diet, Lifestyle Modification, and Dietary Supplements: A Case Report | 27.3 | 0 | 2 |
| Dietary supplement use among health care professionals enrolled in an online curriculum on herbs and dietary supplements | 27.3 | 0 | 2 |
| Gut health immunomodulatory and anti-inflammatory functions of gut enzyme digested high protein micro-nutrient dietary supplement-Enprocal | 27.3 | 0 | 2 |
| Review article: probiotics and prebiotics in irritable bowel syndrome | 27.3 | 0 | 2 |
| Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews | 27.3 | 0 | 2 |
| Effect of capsule 'UB03' containing potential probiotic strains for the treatment of patients with irritable bowel syndrome | 27.3 | 0 | 2 |
| The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. | 27.3 | 0 | 2 |
| Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome | 27.3 | 0 | 2 |
| Dietary fiber in irritable bowel syndrome (Review) | 27.3 | 0 | 2 |
| Irritable bowel syndrome: the role of food in pathogenesis and management | 27.3 | 0 | 2 |
| Functional metagenomics to mine the human gut microbiome for dietary fiber catabolic enzymes | 27.3 | 0 | 2 |
| Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial | 27.3 | 0 | 2 |
| Knowledge and use of dietary supplements by students of College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria | 27.3 | 0 | 2 |
| Food intolerance and skin prick test in treated and untreated irritable bowel syndrome. | 27.3 | 0 | 2 |
| Long-term blood cholesterol-lowering effects of a dietary fiber supplement | 27.3 | 0 | 2 |
| Lactose intolerance and irritable bowel syndrome | 27.3 | 0 | 2 |
| Dietary fiber supplements: effects in obesity and metabolic syndrome and relationship to gastrointestinal functions | 27.3 | 0 | 2 |
| A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial | 27.3 | 0 | 2 |
| Probiotics and prebiotics and food intolerance | 27.3 | 0 | 2 |
| Progress in development of an integrated dietary supplement ingredient database at the NIH Office of Dietary Supplements | 27.3 | 0 | 2 |
| Irritable bowel syndrome: a microbiome-gut-brain axis disorder? | 27.3 | 0 | 2 |
| Progress in developing analytical and label-based dietary supplement databases at the NIH Office of Dietary Supplements | 27.3 | 0 | 2 |
| Regulation of dietary supplements in the United States: understanding the dietary supplement health and education act. | 27.3 | 0 | 2 |
| The low FODMAP diet as a therapy for irritable bowel syndrome | 27.3 | 0 | 2 |
| Simultaneous determination of synthetic phosphodiesterase-5 inhibitors found in a dietary supplement and pre-mixed bulk powders for dietary supplements using high-performance liquid chromatography with diode array detection and liquid chromatography | 27.3 | 0 | 2 |
| Perceived food intolerance in subjects with irritable bowel syndrome-- etiology, prevalence and consequences | 27.3 | 0 | 2 |
| Determination of designer doping agent – 2-ethylamino-1-phenylbutane – in dietary supplements and excretion study following single oral supplement dose | 27.3 | 0 | 2 |
| Knowledge, Attitude and Practice of Pharmacists regarding Dietary Supplements : A Community Pharmacy- based survey in Tehran | 27.3 | 0 | 2 |
| Food intolerance and the irritable bowel syndrome | 27.3 | 0 | 2 |
| Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. | 27.3 | 0 | 2 |
| Designing future prebiotic fiber to target metabolic syndrome | 27.3 | 0 | 2 |
| Overgrowth of the indigenous gut microbiome and irritable bowel syndrome | 27.3 | 0 | 2 |
| Using probiotics and prebiotics to improve gut health | 27.3 | 0 | 2 |
| Development and validation of an ultra‐performance liquid chromatography method for simultaneous analysis of 20 antihistaminics in dietary supplements | 27.3 | 0 | 2 |
| Sex, body mass index, and dietary fiber intake influence the human gut microbiome | 27.3 | 0 | 2 |
| Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan | 27.3 | 0 | 2 |
| Review: Dietary fiber utilization and its effects on physiological functions and gut health of swine | 27.3 | 0 | 2 |
| Ineffective degradation of immunogenic gluten epitopes by currently available digestive enzyme supplements | 27.3 | 0 | 2 |
| The role of the gut–brain axis in alcohol use disorders | 27.3 | 0 | 2 |
| Regulation of energy balance by a gut–brain axis and involvement of the gut microbiota | 27.3 | 0 | 2 |
| Perceived food intolerance and irritable bowel syndrome in a population 3 years after a giardiasis-outbreak: a historical cohort study | 27.3 | 0 | 2 |
| Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases | 27.3 | 0 | 2 |
| Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Is There a Place for Dietary Fiber Supplements in Weight Management? | 27.3 | 0 | 2 |
| Canadian Digestive Health Foundation Public Impact Series 3: Irritable Bowel Syndrome in Canada. Incidence, Prevalence, and Direct and Indirect Economic Impact | 27.3 | 0 | 2 |
| Effects of a lipid-encapsulated zinc oxide supplement on growth performance and intestinal morphology and digestive enzyme activities in weanling pigs | 27.3 | 0 | 2 |
| The role of food intolerance in irritable bowel syndrome | 27.3 | 0 | 2 |
| Nutritional supplements modulate fluorescent protein-bound advanced glycation endproducts and digestive enzymes related to type 2 diabetes mellitus | 27.3 | 0 | 2 |
| Altered gut microbiome in a mouse model of Gulf War Illness causes neuroinflammation and intestinal injury via leaky gut and TLR4 activation | 27.3 | 0 | 2 |
| Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial | 27.3 | 0 | 2 |
| Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats | 27.3 | 0 | 2 |
| Experimental support for the effects of a probiotic/digestive enzyme supplement on serum cholesterol concentrations and the intestinal microbiome | 27.3 | 0 | 2 |
| BJSM reviews: A-Z of nutritional supplements: dietary supplements, sports nutrition foods and Ergogenic aids for health and performance Part 3. | 27.3 | 0 | 2 |
| BJSM reviews: A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance Part 4. | 27.3 | 0 | 2 |
| BJSM reviews: A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance Part 5. | 27.3 | 0 | 2 |
| Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| BJSM reviews: a--z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance part 7. | 27.3 | 0 | 2 |
| BJSM reviews: A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance part 8. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance Part 9. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance--part 10. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance Part 11. | 27.3 | 0 | 2 |
| Bacterial metabolic 'toxins': a new mechanism for lactose and food intolerance, and irritable bowel syndrome. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance--part 12. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance--Part 13. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance Part 14. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: part 15. | 27.3 | 0 | 2 |
| BJSM reviews: A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance--Part 16. | 27.3 | 0 | 2 |
| Relationship between molecular structure of cereal dietary fiber and health effects: focus on glucose/insulin response and gut health | 27.3 | 0 | 2 |
| BJSM reviews: A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance. Part 17. | 27.3 | 0 | 2 |
| BJSMreviews: A to Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance—Part 18 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance—Part 19: Table 1 | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance-Part 20. | 27.3 | 0 | 2 |
| A to Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance--Part 21. | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance—Part 22 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance—Part 23 | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: part 24. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance - part 25. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance--part 26. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance--Part 27. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance - part 28. | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance--Part 29. | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance—Part 30 | 27.3 | 0 | 2 |
| A to Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance—Part 31 | 27.3 | 0 | 2 |
| A to Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: part 32. | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance—Part 33 | 27.3 | 0 | 2 |
| A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance-Part 34. | 27.3 | 0 | 2 |
| Viscous versus nonviscous soluble fiber supplements: mechanisms and evidence for fiber-specific health benefits | 27.3 | 0 | 2 |
| A common cause of irritable bowel syndrome and diverticulitis: chronic distal colon distention from sedentary behavior and excessive dietary fiber | 27.3 | 0 | 2 |
| The Relationship of Food Intolerance and Irritable Bowel Syndrome in Adults | 27.3 | 0 | 2 |
| Dietary Supplements and Medical Foods for Osteopenia and Osteoporosis | 27.3 | 0 | 2 |
| Effects of dietary fiber on digestive enzyme activity and bile acids in the small intestine | 27.3 | 0 | 2 |
| Enzymatic-gravimetric determination in foods of dietary fiber as sum of insoluble and soluble fiber fractions: summary of collaborative study. | 27.3 | 0 | 2 |
| Dietary fiber and digestive health in children | 27.3 | 0 | 2 |
| Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet | 27.3 | 0 | 2 |
| Bioelectrical impedance vector analysis in patients with irritable bowel syndrome on a low FODMAP diet: a pilot study. | 27.3 | 0 | 2 |
| IMPACT OF FOOD ENRICHED WITH DIETARY FIBER ON PATIENTS WITH CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME. | 27.3 | 0 | 2 |
| Endometriosis in patients with irritable bowel syndrome: Specific symptomatic and demographic profile, and response to the low FODMAP diet | 27.3 | 0 | 2 |
| Irritable bowel syndrome, the microbiota and the gut-brain axis. | 27.3 | 0 | 2 |
| Effect of γ-aminobutyric acid on digestive enzymes, absorption function, and immune function of intestinal mucosa in heat-stressed chicken | 27.3 | 0 | 2 |
| The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer's Disease | 27.3 | 0 | 2 |
| The Gut Microbiome in Irritable Bowel Syndrome and Other Functional Bowel Disorders | 27.3 | 0 | 2 |
| A comparative study of the digestive enzymes in the hepatopancreas of Jonah crab (Cancer borealis) and rock crab (Cancer irroratus) | 27.3 | 0 | 2 |
| The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a first-line therapy? | 27.3 | 0 | 2 |
| Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome | 27.3 | 0 | 2 |
| Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating | 27.3 | 0 | 2 |
| Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome. | 27.3 | 0 | 2 |
| The low FODMAP diet: fundamental therapy in the management of irritable bowel syndrome | 27.3 | 0 | 2 |
| Dietary Practices and Fodmaps in South Asia: Applicability of the Low Fodmap Diet to Patients with Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Irritable bowel syndrome and dietary fiber | 27.3 | 0 | 2 |
| Drug therapy reviews: Dietary fiber and fiber supplements in the therapy of gastrointestinal disorders | 27.3 | 0 | 2 |
| Dietary fiber and fiber supplements in the therapy of gastrointestinal disorders | 27.3 | 0 | 2 |
| Understanding the gut microbiome of dairy calves: Opportunities to improve early-life gut health | 27.3 | 0 | 2 |
| Irritable bowel syndrome and food intolerance. | 27.3 | 0 | 2 |
| Determinants of dietary supplement use--healthy individuals use dietary supplements | 27.3 | 0 | 2 |
| The effects of two dietary fiber supplements on gastrointestinal transit, stool weight and frequency, and bacterial flora, and fecal bile acids in normal subjects | 27.3 | 0 | 2 |
| The Low FODMAP Diet for Treatment of Irritable Bowel Syndrome and Other Gastrointestinal Disorders | 27.3 | 0 | 2 |
| Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae | 27.3 | 0 | 2 |
| Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii | 27.3 | 0 | 2 |
| Dietary survey and total dietary fiber intake in patients with irritable bowel syndrome attending a tertiary referral hospital. | 27.3 | 0 | 2 |
| Management of the irritable bowel syndrome. Food intolerance may play a part | 27.3 | 0 | 2 |
| BJSM reviews: A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance Part 6: Table 1 | 27.3 | 0 | 2 |
| On call. Would you suggest I try taking a probiotic supplement for general colon health? I have a sensitive stomach and sometimes suffer from constipation | 27.3 | 0 | 2 |
| Adequate dietary fiber supplement and TONE can help avoid surgery in most patients with advanced hemorrhoids. | 27.3 | 0 | 2 |
| Dietary fiber and intestinal adaptation: effects on intestinal and pancreatic digestive enzyme activities | 27.3 | 0 | 2 |
| Irritable bowel syndrome: is the search for lactose intolerance justified? | 27.3 | 0 | 2 |
| Prevalence and Presentation of Lactose Intolerance and Effects on Dairy Product Intake in Healthy Subjects and Patients With Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Lactose intolerance in different types of irritable bowel syndrome in north Indians | 27.3 | 0 | 2 |
| Is lactose intolerance implicated in the development of post-infectious irritable bowel syndrome or functional diarrhoea in previously asymptomatic people? | 27.3 | 0 | 2 |
| Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis | 27.3 | 0 | 2 |
| Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption | 27.3 | 0 | 2 |
| Dietary fiber and total enteral nutrition: fermentative assessment of five fiber supplements | 27.3 | 0 | 2 |
| Fiber supplements for irritable bowel syndrome: do they really make a difference? | 27.3 | 0 | 2 |
| Prevalence of lactose intolerance in patients with diarrhea-predominant irritable bowel syndrome: data from a tertiary center in southern China | 27.3 | 0 | 2 |
| Prebiotic Dietary Fiber and Gut Health: Comparing the in Vitro Fermentations of Beta-Glucan, Inulin and Xylooligosaccharide | 27.3 | 0 | 2 |
| The Fiber Gap and the Disappearing Gut Microbiome: Implications for Human Nutrition | 27.3 | 0 | 2 |
| Subjective lactose intolerance in apparently healthy adults in southern Iran: Is it related to irritable bowel syndrome? | 27.3 | 0 | 2 |
| Speciation analysis of arsenic in prenatal and children's dietary supplements using microwave-enhanced extraction and ion chromatography–inductively coupled plasma mass spectrometry | 27.3 | 0 | 2 |
| Quality and antioxidant response of gilthead seabream (Sparus aurata L.) to dietary supplements of fenugreek (Trigonella foenum graecum) alone or combined with probiotic strains. | 27.3 | 0 | 2 |
| Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial | 27.3 | 0 | 2 |
| The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS). | 27.3 | 0 | 2 |
| Effect of insoluble fiber supplementation applied at different ages on digestive organ weight and digestive enzymes of layer-strain poultry. | 27.3 | 0 | 2 |
| “But we're not hypochondriacs”: The changing shape of gluten-free dieting and the contested illness experience | 27.3 | 0 | 2 |
| Serotonin: A mediator of the gut–brain axis in multiple sclerosis | 27.3 | 0 | 2 |
| Intestinal microbiome-gut-brain axis and irritable bowel syndrome. | 27.3 | 0 | 2 |
| Evidence for PMAT- and OCT-like biogenic amine transporters in a probiotic strain of Lactobacillus: Implications for interkingdom communication within the microbiota-gut-brain axis | 27.3 | 0 | 2 |
| Lactose intolerance in irritable bowel syndrome patients with diarrhoea: the roles of anxiety, activation of the innate mucosal immune system and visceral sensitivity | 27.3 | 0 | 2 |
| Twenty Years of the Dietary Supplement Health and Education Act—How Should Dietary Supplements Be Regulated? , | 27.3 | 0 | 2 |
| Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome | 27.3 | 0 | 2 |
| Letter: bias in clinical trials of the symptomatic effects of the low FODMAP diet for irritable bowel syndrome-getting the facts right. Authors' reply. | 27.3 | 0 | 2 |
| Letter: bias in clinical trials of the symptomatic effects of the low FODMAP diet for irritable bowel syndrome-getting the facts right. | 27.3 | 0 | 2 |
| The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice | 27.3 | 0 | 2 |
| Perception of lactose intolerance in irritable bowel syndrome patients | 27.3 | 0 | 2 |
| Treatment of Irritable Bowel Syndrome With Saccharomyces boulardii | 27.3 | 0 | 2 |
| Computer access to research on dietary supplements: a database of federally funded dietary supplement research | 27.3 | 0 | 2 |
| Easing Concerns About the Low FODMAP Diet in Patients With Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Effects of soy hull pectin and insoluble fiber on physicochemical and oxidative characteristics of fresh and frozen/thawed beef patties | 27.3 | 0 | 2 |
| Role of irritable bowel syndrome in subjective lactose intolerance | 27.3 | 0 | 2 |
| Determining compliance with a dietary fiber supplement | 27.3 | 0 | 2 |
| Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome | 27.3 | 0 | 2 |
| Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. | 27.3 | 0 | 2 |
| Low-protein diets affect ileal amino acid digestibility and gene expression of digestive enzymes in growing and finishing pigs | 27.3 | 0 | 2 |
| Can low FODMAP diet be considered as first-line therapy in the management of irritable bowel syndrome? | 27.3 | 0 | 2 |
| LC-ESI-MS/MS analysis of phosphodiesterase-5 inhibitors and their analogues in foods and dietary supplements in Korea | 27.3 | 0 | 2 |
| Determination of selected biogenic amines in Acacia rigidula plant materials and dietary supplements using LC–MS/MS methods | 27.3 | 0 | 2 |
| Editorial: gut-directed hypnotherapy or low FODMAP diet for the treatment of irritable bowel syndrome? | 27.3 | 0 | 2 |
| Dietary Challenge Tests: Identifying Food Intolerance as a Cause of Symptoms in Irritable Bowel Syndrome Patients | 27.3 | 0 | 2 |
| Food intolerance and irritable bowel syndrome of childhood: clinical efficacy of oral sodium cromoglycate and elimination diet | 27.3 | 0 | 2 |
| A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. | 27.3 | 0 | 2 |
| The gut microbiome and irritable bowel syndrome. | 27.3 | 0 | 2 |
| Fiber Supplements Derived From Sugarcane Stem, Wheat Dextrin and Psyllium Husk Have Different Effects on the Human Gut Microbiota | 27.3 | 0 | 2 |
| Highly sensitive on-site detection of drugs adulterated in botanical dietary supplements using thin layer chromatography combined with dynamic surface enhanced Raman spectroscopy | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 40: Table 1 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 41 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 42 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 43 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 44: Table 1 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 45 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 46 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 47 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 48 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance – Part 35 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance—Part 37 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 36 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 38 | 27.3 | 0 | 2 |
| A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: part 39: Table 1 | 27.3 | 0 | 2 |
| The Gut Microbiome and Digestive Health - A New Frontier | 27.3 | 0 | 2 |
| Dietary fiber and protein fermentation in the intestine of swine and their interactive effects on gut health and on the environment: A review | 27.3 | 0 | 2 |
| Flaxseed dietary fiber supplements for suppression of appetite and food intake | 27.3 | 0 | 2 |
| IgG-Mediated Food Intolerance in Irritable Bowel Syndrome: A Real Phenomenon or an Epiphenomenom? | 27.3 | 0 | 2 |
| Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome | 27.3 | 0 | 2 |
| Probiotics for lactose intolerance and irritable bowel syndrome | 27.3 | 0 | 2 |
| FOOD INTOLERANCE | Lactose Intolerance | 27.3 | 0 | 2 |
| Early experience with a low FODMAP diet in Asian patients with irritable bowel syndrome | 27.3 | 0 | 2 |
| Low FODMAP Plus PEG 3350 for the Treatment of Patients With Irritable Bowel Syndrome-Constipation | 27.3 | 0 | 2 |
| Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment | 27.3 | 0 | 2 |
| Gut Health Response to Dietary Fiber | 27.3 | 0 | 2 |
| Effects of GlutenShield, a Prebiotic, Probiotic, and Enzyme Supplement, on the Gut Microbiome of Adults With GI Symptoms | 27.3 | 0 | 2 |
| The Effects of Dietary Fiber on the Gut Microbiome and HDL Particles of Human Subjects | 27.3 | 0 | 2 |
| Marine Protein Hydrolysate as Dietary Supplement in Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS) | 27.3 | 0 | 2 |
| A Comparison of Changes in Bone Density With the Same Bone-health Plan, But With Different Bone-health Supplements | 27.3 | 0 | 2 |
| Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy) | 27.3 | 0 | 2 |
| Self-reported Food Intolerance in Korean Patients With Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Intravenous Chemotherapy and Plant-based Dietary Supplements | 27.3 | 0 | 2 |
| Effect of Serotonergic Stimulation on the Gut-brain Axis | 27.3 | 0 | 2 |
| Prebiotic Fiber Supplement in T1DM Children | 27.3 | 0 | 2 |
| Food Allergy Vs Food Intolerance in Patients With Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Dietary fiber and risk of irritable bowel syndrome: a case-control study | 27.3 | 0 | 2 |
| Diets in Symptom Relief and the Influence of Quality of Life in People With Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| New Stage 1 Formula on Gut Comfort and Gut Health | 27.3 | 0 | 2 |
| Irritable Bowel Syndrome and Low FODMAP Diet | 27.3 | 0 | 2 |
| Irritable Bowel Syndrome and Food Sensitivity | 27.3 | 0 | 2 |
| Fiber Health Benefits | 27.3 | 0 | 2 |
| Endomicroscopy, IBS and Food Intolerance | 27.3 | 0 | 2 |
| Effects of Dietary Supplements on Response to Air Pollution | 27.3 | 0 | 2 |
| Gulf War Digestive Health Study | 27.3 | 0 | 2 |
| Saccharomyces Boulardii in Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Effect of Dietary Fiber Supplement on the Intestinal Microbiota Among Schizophrenia Patients | 27.3 | 0 | 2 |
| Mediterranean Diet and the Gut Microbiome | 27.3 | 0 | 2 |
| Gluten-free Diet in Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| β-galactosidase Producing Probiotic Strains to Improve Lactose Digestion | 27.3 | 0 | 2 |
| Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Effects of Wine Grape Pomace Flour Used as a Dietary Supplement on Metabolic Syndrome Components | 27.3 | 0 | 2 |
| Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer | 27.3 | 0 | 2 |
| The Effect of a Low FODMAP Oral Nutrition Supplement On Breath Hydrogen Response In Healthy Human Subjects | 27.3 | 0 | 2 |
| Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients | 27.3 | 0 | 2 |
| Multi-strain Probiotic in the Management of IBS-D | 27.3 | 0 | 2 |
| A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Use of a Dietary Supplement to Support Digestive Health in Children With Chronic Diarrhea | 27.3 | 0 | 2 |
| Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II) | 27.3 | 0 | 2 |
| A Pilot Study of Cognitive-Behaviour Therapy for Irritable Bowel Syndrome and the Gut Microbiome | 27.3 | 0 | 2 |
| Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance | 27.3 | 0 | 2 |
| Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome | 27.3 | 0 | 2 |
| Some aspects of colonic microbial activity in irritable bowel syndrome associated with food intolerance | 27.3 | 0 | 2 |
| Dietary fiber supplements: effects on serum and liver lipids and on liver phospholipid composition in rats | 27.3 | 0 | 2 |
| The irritable bowel syndrome: the possible link between dietary fiber deficiency and disturbed intestinal motility | 27.3 | 0 | 2 |
| Food intolerance, atopy, and irritable bowel syndrome | 27.3 | 0 | 2 |
| The effect of soluble fiber dietary supplement on constipation in 3 patients with dysphagia who suffered from cerebral infarction with special reference to serum diamine oxidase activity | 27.3 | 0 | 2 |
| Hypocholesterolemic effects of a dietary fiber supplement | 27.3 | 0 | 2 |
| Dietary fiber viscosity and amino acid digestibility, proteolytic digestive enzyme activity and digestive organ weights in growing rats | 27.3 | 0 | 2 |
| Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome | 27.3 | 0 | 2 |
| Food intolerance, prostaglandins, and irritable bowel syndrome | 27.3 | 0 | 2 |
| Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities | 27.3 | 0 | 2 |
| Impact of Nutritional Supplementation on Sleep Quality and Gut Microbiome Composition in Older Adults | 27.3 | 0 | 2 |
| Lactose intolerance and irritable bowel syndrome | 27.3 | 0 | 2 |
| FDA regulation of ingredients in dietary supplements after passage of the Dietary Supplement Health and Education Act of 1994: an update | 27.3 | 0 | 2 |
| Guidelines for the promotion of dietary supplements: examining government regulation five years after enactment of the Dietary Supplement Health and Education Act of 1994 | 27.3 | 0 | 2 |
| Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients | 27.3 | 0 | 2 |
| Microbiome of the Ageing Gut and Its Effect on Human Gut Health and Cognition. | 27.3 | 0 | 2 |
| The Dietary Supplement and Health Education Act and Supplements: Dietary and Nutritional Supplements Need No More Regulations | 27.3 | 0 | 2 |
| Proteases in irritable bowel syndrome: a lot more than just digestive enzymes | 27.3 | 0 | 2 |
| Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study | 27.3 | 0 | 2 |
| Dietary fiber assessment of patients with irritable bowel syndrome from Northern India | 27.3 | 0 | 2 |
| Dietary intake of a group of patients with irritable bowel syndrome; relation between dietary fiber and symptoms | 27.3 | 0 | 2 |
| Food intolerance and allergy in the irritable bowel syndrome | 27.3 | 0 | 2 |
| Case study: The effectiveness of a dietary supplement regimen in reducing IgG-mediated food sensitivity in ADHD | 27.3 | 0 | 2 |
| Sense and food sensitivity: coping with allergies and food intolerance | 27.3 | 0 | 2 |
| Influence of the Dietary Supplement Health and Education Act on Consumer Beliefs About the Safety and Effectiveness of Dietary Supplements | 27.3 | 0 | 2 |
| Using dietary supplement containing dietary fiber, fermented wine yeasts, vitamins and minerals, under the influence of dust-gas mixture. The experiments on laboratory animals | 27.3 | 0 | 2 |
| A genetic variant of the CAPN10 gene in Mexican subjects with dyslipidemia is associated with increased HDL-cholesterol concentrations after the consumption of a soy protein and soluble fiber dietary portfolio | 27.3 | 0 | 2 |
| Probiotic supplement (Lactobacillus acidophilus and bulgaricus) utility in the treatment of irritable bowel syndrome | 27.3 | 0 | 2 |
| Positive effects of wheat bran for digestive health; scientific evidence | 27.3 | 0 | 2 |
| UHPLC–UV method for the determination of flavonoids in dietary supplements and for evaluation of their antioxidant activities | 27.3 | 0 | 2 |
| A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States | 27.3 | 0 | 2 |
| RNA-Seq reveals the dynamic and diverse features of digestive enzymes during early development of Pacific white shrimp Litopenaeus vannamei | 27.3 | 0 | 2 |
| Digestive enzyme supplements: replacement therapy for individuals unwilling to take porcine products | 27.3 | 0 | 2 |
| protein powder | 27.3 | 0 | 2 |
| WGO Celebrates World Digestive Health Day 2016 Your Diet and Gut Health! | 27.3 | 0 | 2 |
| Low FODMAP Diet in the Treatment of Irritable Bowel Syndrome: Is It the End of the Road or the Beginning of a Journey? | 27.3 | 0 | 2 |
| The Impact of Dietary Treatment in Patients With Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Adherence to a Low FODMAP Diet in Relation to Symptoms of Irritable Bowel Syndrome in Iranian Adults | 27.3 | 0 | 2 |
| Complementary effects of cereal and pulse polyphenols and dietary fiber on chronic inflammation and gut health | 27.3 | 0 | 2 |
| Editorial: gut-directed hypnotherapy or low FODMAP diet for the treatment of irritable bowel syndrome? Authors' reply | 27.3 | 0 | 2 |
| Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial | 27.3 | 0 | 2 |
| Beyond Irritable Bowel Syndrome: The Efficacy of the Low Fodmap Diet for Improving Symptoms in Inflammatory Bowel Diseases and Celiac Disease | 27.3 | 0 | 2 |
| Targeting the Microbiota, from Irritable Bowel Syndrome to Mood Disorders: Focus on Probiotics and Prebiotics | 27.3 | 0 | 2 |
| The gut microbiome and irritable bowel syndrome: State of art review | 27.3 | 0 | 2 |
| Nutritional Supplements: Certification programs to ensure quality dietary supplements | 27.3 | 0 | 2 |
| Midgut digestive enzyme activity in the dragonfly, Tramea virginia (Rambur) (Anisoptera: Libellulidae) | 27.3 | 0 | 2 |
| Is There a Correlation Between Irritable Bowel Syndrome and Lactose Intolerance? | 27.3 | 0 | 2 |
| Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome | 27.3 | 0 | 2 |
| Metformin reduces aging-related leaky gut and improves cognitive function by beneficially modulating gut microbiome/goblet cell/mucin axis | 27.3 | 0 | 2 |
| Clinical Efficacy Of Lactase Enzyme Supplement In Infant Colic: A Randomised Controlled Trial | 27.3 | 0 | 2 |
| A synbiotic concept containing spore-forming Bacillus strains and a prebiotic fiber blend consistently enhanced metabolic activity by modulation of the gut microbiome in vitro | 27.3 | 0 | 2 |
| Lactose intolerance but not lactose maldigestion is more frequent in patients with irritable bowel syndrome than in healthy controls: A meta-analysis | 27.3 | 0 | 2 |
| ANALYSIS OF LACTOSE INTOLERANCE IN STUDENTS WITH SUGGESTIVE SYMPTOMS OF IRRITABLE BOWEL SYNDROME | 27.3 | 0 | 2 |
| Impact of combining acerola by-product with a probiotic strain on a gut microbiome model | 27.3 | 0 | 2 |
| Nutrient Intake, Diet Quality, and Diet Diversity in Irritable Bowel Syndrome and the Impact of the Low FODMAP Diet | 27.3 | 0 | 2 |
| Binge alcohol and HIV: leaky gut and neurodegeneration through the gut-brain axis | 27.3 | 0 | 2 |
| Improvement in Gastroesophageal Reflux Symptoms From a Food-grade Maltosyl-isomaltooligosaccharide Soluble Fiber Supplement: A Case Series | 27.3 | 0 | 2 |
| Effects of the Ratio of Insoluble Fiber to Soluble Fiber in Gestation Diets on Sow Performance and Offspring Intestinal Development | 27.3 | 0 | 2 |
| IRRITABLE BOWEL SYNDROME, FOOD INTOLERANCE AND NON- CELIAC GLUTEN SENSITIVITY. A NEW CLINICAL CHALLENGE | 27.3 | 0 | 2 |
| The gut microbiome and pharmacology: a prescription for therapeutic targeting of the gut-brain axis | 27.3 | 0 | 2 |
| Safety and Effect of a Low- and High-Dose Multi-Strain Probiotic Supplement on Microbiota in a General Adult Population: A Randomized, Double-Blind, Placebo-Controlled Study | 27.3 | 0 | 2 |
| Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management? | 27.3 | 0 | 2 |
| A Mechanistic Model of Gut-Brain Axis Perturbation and High-Fat Diet Pathways to Gut Microbiome Homeostatic Disruption, Systemic Inflammation, and Type 2 Diabetes | 27.3 | 0 | 2 |
| [Effect of healthy eating before intervention with a low FODMAP diet in pediatric patients with irritable bowel syndrome] | 27.3 | 0 | 2 |
| Food Sensitivity Testing and Elimination Diets in the Management of Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Dietary fiber isolated from sweet potato residues promotes a healthy gut microbiome profile | 27.3 | 0 | 2 |
| An Overview of Fiber and Fiber Supplements for Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Acute oral methylmercury exposure perturbs the gut microbiome and alters gut-brain axis related metabolites in rats | 27.3 | 0 | 2 |
| Effects of Added Dietary Fiber and Rearing System on the Gut Microbial Diversity and Gut Health of Chickens | 27.3 | 0 | 2 |
| Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome? | 27.3 | 0 | 2 |
| Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply | 27.3 | 0 | 2 |
| Soluble Fiber and Insoluble Fiber Regulate Colonic Microbiota and Barrier Function in a Piglet Model | 27.3 | 0 | 2 |
| Investigating appropriate molecular and chemical methods for ingredient identity testing of plant-based protein powder dietary supplements | 27.3 | 0 | 2 |
| Probiotics, prebiotics, and low FODMAP diet for irritable bowel syndrome - What is the current evidence? | 27.3 | 0 | 2 |
| Effects of Low-FODMAPS Diet on Irritable Bowel Syndrome Symptoms and Gut Microbiome | 27.3 | 0 | 2 |
| The Association between Prebiotic Fiber Supplement Use and Colorectal Cancer Risk and Mortality in the Women's Health Initiative | 27.3 | 0 | 2 |
| [Gluten-free diet and low FODMAP diet: no or minor evidence for treating irritable bowel syndrome] | 27.3 | 0 | 2 |
| Review on Bile Acids: Effects of the Gut Microbiome, Interactions with Dietary Fiber, and Alterations in the Bioaccessibility of Bioactive Compounds | 27.3 | 0 | 2 |
| Dietary Supplement Use in Gastrointestinal Symptom Management and Effect on Hopelessness Levels in Patients With Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Why Do Athletes Choose Dietary Supplements? Reliability and Validity of the Dietary Supplement Choice Questionnaire (DSCQ) among Japanese College Athletes | 27.3 | 0 | 2 |
| The Effect of a Low FODMAP Diet in Irritable Bowel Syndrome Patients | 27.3 | 0 | 2 |
| Help healthy patients stay healthy. This month: reducing practice aggravation, vegetarians and vitamin B12, who needs vitamin supplements, marathons and hypothermia, effect of vitamin C on cholesterol, how much vitamin C to take, effect of dietary s | 27.3 | 0 | 2 |
| The Effect of Isolated Dietary Fiber Supplements on Markers of Metabolic Diseases in Human Intervention Studies: A Systematic Review (P08-077-19) | 27.3 | 0 | 2 |
| PSXII-9 The dietary supplement of the combined soluble fiber during gestation alleviate oxidative stress and improve sow and piglet performance | 27.3 | 0 | 2 |
| A Partnership in the Making: Metabolic Phenotype Determined by the Combination of Dietary Fiber and the Gut Microbiome (FS07-03-19) | 27.3 | 0 | 2 |
| The gut microbiome modulates gut-brain axis glycerophospholipid metabolism in a region-specific manner in a nonhuman primate model of depression | 27.3 | 0 | 2 |
| β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria | 27.3 | 0 | 2 |
| Insufficient evidence of the effect of the low FODMAP diet on irritable bowel syndrome | 27.3 | 0 | 2 |
| The case for soluble fiber. More reason to eat your fruits and vegetables: new research may have found the key to how a fiber-rich diet is disease-protective | 27.3 | 0 | 2 |
| Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply | 27.3 | 0 | 2 |
| Dietary supplement safety. You've heard all the warnings about dietary supplements. Here are a few that men should use with caution or avoid | 27.3 | 0 | 2 |
| Immune status estimation algorithm in irritable bowel syndrome patients with food intolerance | 27.3 | 0 | 2 |
| Challenges of the low FODMAP diet for managing irritable bowel syndrome and approaches to their minimisation and mitigation | 27.3 | 0 | 2 |
| Awareness and Attitudes of Gut Health, Probiotics and Prebiotics in Australian Adults | 27.3 | 0 | 2 |
| Irritable Bowel Syndrome and lactose intolerance: the importance of differential diagnosis. A monocentric study | 27.3 | 0 | 2 |
| The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Contro | 27.3 | 0 | 2 |
| The Gut Microbiome as a Component of the Gut-Brain Axis in Cognitive Health | 27.3 | 0 | 2 |
| Sex-Specific Differences in the Gut Microbiome in Response to Dietary Fiber Supplementation in IL-10-Deficient Mice | 27.3 | 0 | 2 |
| Gut Health-Promoting Benefits of a Dietary Supplement of Vitamins with Inulin and Acacia Fibers in Rats | 27.3 | 0 | 2 |
| Effects of Dietary Guidance without Dietary Fiber Supplements on the Symptoms, Quality of Life, and Dietary Intake in Patients with Fecal Incontinence | 27.3 | 0 | 2 |
| Impact of a Gastrointestinal Stable Probiotic Supplement Bacillus coagulans LBSC on Human Gut Microbiome Modulation | 27.3 | 0 | 2 |
| Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome | 27.3 | 0 | 2 |
| Irritable Bowel Syndrome and lactose intolerance. A challenging overlap | 27.3 | 0 | 2 |
| Impact of Gallic Acid on Gut Health: Focus on the Gut Microbiome, Immune Response, and Mechanisms of Action | 27.3 | 0 | 2 |
| Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health | 27.3 | 0 | 2 |
| Low Fermentable Oligo- Di- and Mono-Saccharides and Polyols (FODMAPs) or Gluten Free Diet: What Is Best for Irritable Bowel Syndrome? | 27.3 | 0 | 2 |
| Is low FODMAP diet effective in children with irritable bowel syndrome? | 27.3 | 0 | 2 |
| Gut Health = Mental Health? The Impact of Diet and Dietary Supplements on Mood Disorders | 27.3 | 0 | 2 |
| Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics | 27.3 | 0 | 2 |
| Increasing Expiratory Hydrogen in Lactose Intolerance Is Associated with Additional Food Intolerance/Malabsorption | 27.3 | 0 | 2 |
| The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease | 27.3 | 0 | 2 |
| Fructan-sensitive children with irritable bowel syndrome have distinct gut microbiome signatures | 27.3 | 0 | 2 |
| The intervention of unique plant polysaccharides - Dietary fiber on depression from the gut-brain axis | 27.3 | 0 | 2 |
| Fecal Microbiota Transplantation Donor and Dietary Fiber Intervention Collectively Contribute to Gut Health in a Mouse Model | 27.3 | 0 | 2 |
| Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome | 27.3 | 0 | 2 |
| Effects of Chang-Kang-Fang Formula on the Microbiota-Gut-Brain Axis in Rats With Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Natural capsicum extract replacing chlortetracycline enhances performance via improving digestive enzyme activities, antioxidant capacity, anti-inflammatory function, and gut health in weaned pigs | 27.3 | 0 | 2 |
| Effects of novel probiotic strains of Bacillus pumilus and Bacillus subtilis on production, gut health, and immunity of broiler chickens raised under suboptimal conditions | 27.3 | 0 | 2 |
| Diet and gut health in residents of a retirement village | 27.3 | 0 | 2 |
| A feasibility study to investigate the impact of a dietitian-led low FODMAP diet group education programme for adults with Irritable Bowel Syndrome (IBS). | 27.3 | 0 | 2 |
| Dietary Modification for the Restoration of Gut Microbiome and Management of Symptoms in Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Multi-strain Probiotic Formulation Reverses Maternal Separation and Chronic Unpredictable Mild Stress-Generated Anxiety- and Depression-like Phenotypes by Modulating Gut Microbiome–Brain Activity in Rats | 27.3 | 0 | 2 |
| Competitive Exclusion Bacterial Culture Derived from the Gut Microbiome of Nile Tilapia (Oreochromis niloticus) as a Resource to Efficiently Recover Probiotic Strains: Taxonomic, Genomic, and Functional Proof of Concept | 27.3 | 0 | 2 |
| Study of Probiotic Use After Childbirth in Relation to Emotional Well-Being | 27.3 | 0 | 2 |
| Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhea-predominant Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Trial to Evaluate Dietary Supplements to Maintain Gut Health During Travel | 27.3 | 0 | 2 |
| Efficacy and Safety of Saccharomyces Boulardii in the Treatment of Small Intestinal Bacterial Overgrowth | 27.3 | 0 | 2 |
| Rifaximin Therapy vs Low FODMAP Diet In IBS | 27.3 | 0 | 2 |
| The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) | 27.3 | 0 | 2 |
| Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients | 27.3 | 0 | 2 |
| Comparison Between Low FODMAP and SSRD in IBS | 27.3 | 0 | 2 |
| Efficacy of a Digestive Enzyme Blend | 27.3 | 0 | 2 |
| Tritordeum-based Foods for IBS Symptoms | 27.3 | 0 | 2 |
| Management of patients with food intolerance in irritable bowel syndrome: the development and use of an exclusion diet | 27.3 | 0 | 2 |
| Multi-omics analyses of serum metabolome, gut microbiome and brain function reveal dysregulated microbiota-gut-brain axis in bipolar depression | 27.3 | 0 | 2 |
| Q115671425 | 27.3 | 0 | 2 |
| Effects of Dietary Supplement of Schizochytrium Meal on Growth, Fatty Acid Profile and Activities of Digestive Enzymes in Turbot (Scophthalmus maximus L.) Larvae | 27.3 | 0 | 2 |
| Low FODMAP diet & prebiotic β-galactooligosaccharides improve irritable bowel syndrome and response to low FODMAP is predicted by urine and faecal metabolites: a randomised controlled trial | 27.3 | 0 | 2 |
| Dietary fiber of psyllium husk (Plantago ovata) as a potential antioxidant and hepatoprotective agent against CCl4-induced hepatic damage in rats | 27.3 | 0 | 2 |
| Lignin as a purified dietary fiber supplement for piglets | 27.3 | 0 | 2 |
| Children with Small Bowel Lactase Enzyme Deficiency Have Positive Genetic Maker for Lactose Intolerance the C/T -13910 Hypolactasia Variant | 27.3 | 0 | 2 |
| Prevalence and Efficacy of Dietary Supplements and Alternative Forms of Treatment for Irritable Bowel Syndrome (IBS) | 27.3 | 0 | 2 |
| SUN-PO150: Evaluation of Dietary Fiber Intake and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Practical guidelines for gut microbiome analysis in microbiota-gut-brain axis research | 27.3 | 0 | 2 |
| Sijunzi Tang, Codonopsis Pilosula Polysaccharide and Saccharomyces Boulardii Modulate the Gut Microbiome to Alleviate Dss-Induced Colitis in Mice | 27.3 | 0 | 2 |
| Sa1932 – Effect of Saccharomyces Boulardii Cncm I-745 on the Gut Microbiome As a Complementary Treatment Against Helicobacter Pylori Infection | 27.3 | 0 | 2 |
| Tu1611 – Psychological Flexibility As an Important Feature of Digestive Health for Patients Undergoing Cognitive Behavioral Therapy for Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Sa1936 – Efficacy and Safety of Saccharomyces Boulardii Cncm I -745 in the Treatment of Small Intestinal Bacterial Overgrowth in Patients Suffering Irritable Bowel Syndrome with Diarrhea | 27.3 | 0 | 2 |
| 878 – Gut Microbiome Biomarkers Before and During a Fructan Challenge are Associated with Fructan Sensitivity in Children with Irritable Bowel Syndrome | 27.3 | 0 | 2 |
| Mo1548 – Efficacy, Feasibility, and Safety of the Low Fodmap Diet for Children with Irritable Bowel Syndrome: A Prospective Cohort Study and Phone Survey | 27.3 | 0 | 2 |
| A comparison of dietary fiber supplements in the treatment of mild constipation | 27.3 | 0 | 2 |
| Complimenting gluten free bakery products with dietary fiber: Opportunities and constraints | 27.3 | 0 | 2 |
| Partially Hydrolyzed Guar Gum, an Organoleptically-clean Prebiotic Fiber Ingredient for Dietary Supplements | 27.3 | 0 | 2 |
| Effects of dietary arginine supplementation on growth performance, antioxidant capacity, intestinal digestive enzyme activity, muscle transcriptome, and gut health of Siniperca chuatsi | 27.3 | 0 | 2 |
| Effectiveness of two dietary approaches in improving symptoms and quality of life of individuals with irritable bowel syndrome: Low fodmap diet versus standard diet | 27.3 | 0 | 2 |
| Synergistic influence of hydrolyzed squid processing by-products and Bacillus probiotics as dietary supplements on growth performance, immunological responses, and gut health of juvenile black tiger shrimp fed fishmeal-free diets | 27.3 | 0 | 2 |
| Specific probiotics and prebiotics to improve the quality of life of patients with chronic irritable bowel syndrome | 27.3 | 0 | 2 |
| Lactose Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome is Associated With Mucosal Immune Activation and Anxiety | 27.3 | 0 | 2 |
| Does the Prevalence of Fructose and Lactose Intolerance Differ Between ROME III Subgroups of Functional Dyspepsia (FD) and Irritable Bowel Syndrome (IBS)? | 27.3 | 0 | 2 |
| Evaluation of meat quality of weaned rabbits administered different concentrations of probiotic strain (Saccharomyces boulardii) | 27.3 | 0 | 2 |
| soluble fiber | 27.3 | 0 | 2 |
| insoluble fiber | 27.3 | 0 | 2 |
| Supplementing Dietary Fibers With a Low FODMAP Diet in Irritable Bowel Syndrome: A Randomized Controlled Crossover Trial | 27.3 | 0 | 2 |
| Q135277244 | 27.3 | 0 | 2 |
| Q135408728 | 27.3 | 0 | 2 |
| Q135869810 | 27.3 | 0 | 2 |
| Resistant dextrin | 27.3 | 0 | 2 |
| Q137207319 | 27.3 | 0 | 2 |
| Fuel Supplements | 27.3 | 0 | 2 |
| HeldenPilz | 27.3 | 0 | 2 |
| HiLife Vitamins | 27.3 | 0 | 2 |
| Vitlin | 27.3 | 0 | 2 |
| CalmGut | 27.3 | 0 | 2 |
| trypsin | 17.2 | 0 | 1 |
| Saccharomyces boulardii | 17.2 | 0 | 1 |
| product return | 17.2 | 0 | 1 |
| vitamin K | 17.2 | 0 | 1 |
| inulin | 17.2 | 0 | 1 |
| dietary fiber | 17.2 | 0 | 1 |
| lactose intolerance | 17.2 | 0 | 1 |
| spirulina | 17.2 | 0 | 1 |
| achylia | 17.2 | 0 | 1 |
| chymotrypsin | 17.2 | 0 | 1 |
| trypsinogen | 17.2 | 0 | 1 |
| pancreatin | 17.2 | 0 | 1 |
| Nutrilite | 17.2 | 0 | 1 |
| resistant starch | 17.2 | 0 | 1 |
| human gut flora | 17.2 | 0 | 1 |
| cod liver oil | 17.2 | 0 | 1 |
| iron supplement | 17.2 | 0 | 1 |
| TRX2 | 17.2 | 0 | 1 |
| irritable bowel syndrome | 17.2 | 0 | 1 |
| glucomannan | 17.2 | 0 | 1 |
| Slim Fast | 17.2 | 0 | 1 |
| bodybuilding supplement | 17.2 | 0 | 1 |
| Clean label | 17.2 | 0 | 1 |
| Islamic dietary laws | 17.2 | 0 | 1 |
| Gluten-free, casein-free diet | 17.2 | 0 | 1 |
| Active Hexose Correlated Compound | 17.2 | 0 | 1 |
| food intolerance | 17.2 | 0 | 1 |
| Nu Skin Enterprises | 17.2 | 0 | 1 |
| Haarlem oil | 17.2 | 0 | 1 |
| Salvestrols | 17.2 | 0 | 1 |
| gluten-free diet | 17.2 | 0 | 1 |
| Klamath Lake AFA | 17.2 | 0 | 1 |
| enterotype | 17.2 | 0 | 1 |
| hazelnut spread | 17.2 | 0 | 1 |
| Airborne | 17.2 | 0 | 1 |
| American Health, Inc. | 17.2 | 0 | 1 |
| Atomidine | 17.2 | 0 | 1 |
| Beano | 17.2 | 0 | 1 |
| caloric restriction mimetic | 17.2 | 0 | 1 |
| Canadian Digestive Health Foundation | 17.2 | 0 | 1 |
| Cancell | 17.2 | 0 | 1 |
| Chemins | 17.2 | 0 | 1 |
| CortiSlim | 17.2 | 0 | 1 |
| Dexatrim | 17.2 | 0 | 1 |
| Energy gel | 17.2 | 0 | 1 |
| Ensure | 17.2 | 0 | 1 |
| fodmap | 17.2 | 0 | 1 |
| fat necrosis | 17.2 | 0 | 1 |
| fibre supplements | 17.2 | 0 | 1 |
| Gentech Pharmaceutical | 17.2 | 0 | 1 |
| Geritol | 17.2 | 0 | 1 |
| World Digestive Health Day | 17.2 | 0 | 1 |
| International Scientific Association for Probiotics and Prebiotics | 17.2 | 0 | 1 |
| Jeffrey I. Gordon | 17.2 | 0 | 1 |
| lactase persistence | 17.2 | 0 | 1 |
| Leaky gut | 17.2 | 0 | 1 |
| Liquid oxygen supplement | 17.2 | 0 | 1 |
| Mannan oligosaccharide-based nutritional supplements | 17.2 | 0 | 1 |
| Met-Rx | 17.2 | 0 | 1 |
| Juice Plus+ | 17.2 | 0 | 1 |
| Ocean Nutrition Canada | 17.2 | 0 | 1 |
| Pea protein | 17.2 | 0 | 1 |
| Pharmavite | 17.2 | 0 | 1 |
| Category:Dietary supplements | 17.2 | 0 | 1 |
| quack Miranda warning | 17.2 | 0 | 1 |
| Regulation of food and dietary supplements by the U.S. Food and Drug Administration | 17.2 | 0 | 1 |
| saw palmetto extract | 17.2 | 0 | 1 |
| shelf-stable food | 17.2 | 0 | 1 |
| Souvenaid | 17.2 | 0 | 1 |
| TrimSpa | 17.2 | 0 | 1 |
| Category:Colony forming units | 17.2 | 0 | 1 |
| Category:Digestive enzymes | 17.2 | 0 | 1 |
| ADE | 17.2 | 0 | 1 |
| Template:Digestive enzymes | 17.2 | 0 | 1 |
| Novit | 17.2 | 0 | 1 |
| Genacol | 17.2 | 0 | 1 |
| Hydroxycut | 17.2 | 0 | 1 |
| NITRO FX | 17.2 | 0 | 1 |
| Category:B-Class Dietary supplement articles | 17.2 | 0 | 1 |
| Category:C-Class Dietary supplement articles | 17.2 | 0 | 1 |
| Category:Dietary supplement articles by importance | 17.2 | 0 | 1 |
| Category:Dietary supplement articles by quality | 17.2 | 0 | 1 |
| Category:FA-Class Dietary supplement articles | 17.2 | 0 | 1 |
| Category:FL-Class Dietary supplement articles | 17.2 | 0 | 1 |
| Category:GA-Class Dietary supplement articles | 17.2 | 0 | 1 |
| Category:High-importance Dietary supplement articles | 17.2 | 0 | 1 |
| Category:Low-importance Dietary supplement articles | 17.2 | 0 | 1 |
| Category:NA-Class Dietary supplement pages | 17.2 | 0 | 1 |
| Category:NA-importance Dietary supplement pages | 17.2 | 0 | 1 |
| Category:Start-Class Dietary supplement articles | 17.2 | 0 | 1 |
| Category:Stub-Class Dietary supplement articles | 17.2 | 0 | 1 |
| Category:Top-importance Dietary supplement articles | 17.2 | 0 | 1 |
| Category:Unassessed Dietary supplement articles | 17.2 | 0 | 1 |
| Category:WikiProject Dietary Supplements | 17.2 | 0 | 1 |
| non-fermentable dietary fiber | 17.2 | 0 | 1 |
| Template:Dietary supplement | 17.2 | 0 | 1 |
| pancreas development | 17.2 | 0 | 1 |
| exocrine pancreas development | 17.2 | 0 | 1 |
| penetration of zona pellucida | 17.2 | 0 | 1 |
| zymogen granule | 17.2 | 0 | 1 |
| Category:WikiProject Dietary Supplements articles | 17.2 | 0 | 1 |
| Category:A-Class Dietary supplement articles | 17.2 | 0 | 1 |
| Category:Unknown-importance Dietary supplement articles | 17.2 | 0 | 1 |
| Category:List-Class Dietary supplement articles | 17.2 | 0 | 1 |
| Category:Mid-importance Dietary supplement articles | 17.2 | 0 | 1 |
| International Journal of Probiotics and Prebiotics | 17.2 | 0 | 1 |
| Clinical Nutrition Supplements | 17.2 | 0 | 1 |
| Nutrition and Dietary Supplements | 17.2 | 0 | 1 |
| weight gainer | 17.2 | 0 | 1 |
| Dietary Supplement Health and Education Act of 1994 | 17.2 | 0 | 1 |
| Azerizin | 17.2 | 0 | 1 |
| Fish protein powder | 17.2 | 0 | 1 |
| Juice Plus | 17.2 | 0 | 1 |
| Lipozene | 17.2 | 0 | 1 |
| gut–brain axis | 17.2 | 0 | 1 |
| MuscleTech | 17.2 | 0 | 1 |
| leaky-gut syndrome | 17.2 | 0 | 1 |
| Seasilver | 17.2 | 0 | 1 |
| Metamucil | 17.2 | 0 | 1 |
| Gluten Free Ebola | 17.2 | 0 | 1 |
| Q18208172 | 17.2 | 0 | 1 |
| Dietary Supplement Access and Awareness Act by Susan Davis | 17.2 | 0 | 1 |
| Category:Dietary fiber | 17.2 | 0 | 1 |
| Zinzino | 17.2 | 0 | 1 |
| Cerebos Pacific | 17.2 | 0 | 1 |
| Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome | 17.2 | 0 | 1 |
| The microbiota-gut-brain axis: neurobehavioral correlates, health and sociality | 17.2 | 0 | 1 |
| Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome | 17.2 | 0 | 1 |
| Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection | 17.2 | 0 | 1 |
| U.S. and Canadian pharmacists' attitudes, knowledge, and professional practice behaviors toward dietary supplements: a systematic review | 17.2 | 0 | 1 |
| Effect of gluten free diet on immune response to gliadin in patients with non-celiac gluten sensitivity | 17.2 | 0 | 1 |
| Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? | 17.2 | 0 | 1 |
| Do published guidelines for evaluation of Irritable Bowel Syndrome reflect practice? | 17.2 | 0 | 1 |
| Do nutritional supplements have a role in age macular degeneration prevention? | 17.2 | 0 | 1 |
| The role of "mixed" orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with [...] | 17.2 | 0 | 1 |
| Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya | 17.2 | 0 | 1 |
| WikiProject Dietary Supplements | 17.2 | 0 | 1 |
| The relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestations | 17.2 | 0 | 1 |
| VitaPerk | 17.2 | 0 | 1 |
| Role for protease activity in visceral pain in irritable bowel syndrome | 17.2 | 0 | 1 |
| Alternative medicine consultations and remedies in patients with the irritable bowel syndrome | 17.2 | 0 | 1 |
| Nutritional Supplements and Ergogenic Aids | 17.2 | 0 | 1 |
| Schizophrenia and the gut–brain axis | 17.2 | 0 | 1 |
| Genetics of Lactase Persistence and Lactose Intolerance | 17.2 | 0 | 1 |
| Pioneer in the gluten free diet: Willem-Karel Dicke 1905-1962, over 50 years of gluten free diet | 17.2 | 0 | 1 |
| Q23662209 | 17.2 | 0 | 1 |
| Return Policy | 17.2 | 0 | 1 |
| Self-reported hand and wrist arthritis and occupation: data from the U.S. National Health Interview Survey-Occupational Health Supplement | 17.2 | 0 | 1 |
| Work-relatedness of selected chronic medical conditions and workers' compensation utilization: National Health Interview Survey occupational health supplement data | 17.2 | 0 | 1 |
| Prevalence and work-relatedness of self-reported carpal tunnel syndrome among U.S. workers: analysis of the occupational health supplement data of 1988 National Health Interview Survey | 17.2 | 0 | 1 |
| Dietary supplements for dysmenorrhoea | 17.2 | 0 | 1 |
| Physical activity for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Dietary supplements for chronic gout | 17.2 | 0 | 1 |
| Acupuncture for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Dietary supplements for chronic gout | 17.2 | 0 | 1 |
| Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood | 17.2 | 0 | 1 |
| Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood | 17.2 | 0 | 1 |
| Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood | 17.2 | 0 | 1 |
| Homeopathy for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Homeopathy for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Dietary supplements for preventing postnatal depression | 17.2 | 0 | 1 |
| Dietary supplements for established atopic eczema | 17.2 | 0 | 1 |
| Dietary advice with or without oral nutritional supplements for disease-related malnutrition in adults | 17.2 | 0 | 1 |
| Dietary supplements for preventing postnatal depression | 17.2 | 0 | 1 |
| Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Nutritional supplements for people being treated for active tuberculosis | 17.2 | 0 | 1 |
| Nutritional supplements for people being treated for active tuberculosis | 17.2 | 0 | 1 |
| Psychological treatments for the management of irritable bowel syndrome | 17.2 | 0 | 1 |
| Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood | 17.2 | 0 | 1 |
| Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood | 17.2 | 0 | 1 |
| Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood | 17.2 | 0 | 1 |
| Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood | 17.2 | 0 | 1 |
| Antibiotics for the management of constipation predominant irritable bowel syndrome and chronic constipation | 17.2 | 0 | 1 |
| Tegaserod for the treatment of irritable bowel syndrome and chronic constipation | 17.2 | 0 | 1 |
| Hypnotherapy for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Soy formula for prevention of allergy and food intolerance in infants | 17.2 | 0 | 1 |
| Formulas containing hydrolysed protein for prevention of allergy and food intolerance in infants | 17.2 | 0 | 1 |
| Soy formula for prevention of allergy and food intolerance in infants | 17.2 | 0 | 1 |
| Acupuncture for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Probiotic agents for the treatment of diarrhoea-predominant irritable bowel syndrome | 17.2 | 0 | 1 |
| Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Formulas containing hydrolysed protein for prevention of allergy and food intolerance in infants | 17.2 | 0 | 1 |
| Dietary supplements for established atopic eczema | 17.2 | 0 | 1 |
| Herbal medicines for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Acupuncture for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Hypnotherapy for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Dietary supplements for established atopic eczema | 17.2 | 0 | 1 |
| Psychological treatments for the management of irritable bowel syndrome | 17.2 | 0 | 1 |
| Nutritional supplements for people being treated for active tuberculosis | 17.2 | 0 | 1 |
| Soy formula for prevention of allergy and food intolerance in infants | 17.2 | 0 | 1 |
| Tegaserod for the treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Formulas containing hydrolysed protein for prevention of allergy and food intolerance in infants | 17.2 | 0 | 1 |
| Herbal medicines for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer | 17.2 | 0 | 1 |
| A novel human chymotrypsin-like digestive enzyme | 17.2 | 0 | 1 |
| Enterotypes of the human gut microbiome | 17.2 | 0 | 1 |
| Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? | 17.2 | 0 | 1 |
| Alosetron for irritable bowel syndrome | 17.2 | 0 | 1 |
| Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis | 17.2 | 0 | 1 |
| Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants. | 17.2 | 0 | 1 |
| Prevalence of irritable bowel syndrome: a community survey | 17.2 | 0 | 1 |
| Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells | 17.2 | 0 | 1 |
| Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: correlation of symptom relief with whole gut transit time and stool weight | 17.2 | 0 | 1 |
| Double blind study of ispaghula in irritable bowel syndrome | 17.2 | 0 | 1 |
| The scientific basis for probiotic strains of Lactobacillus | 17.2 | 0 | 1 |
| Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa | 17.2 | 0 | 1 |
| Giardia lamblia infection in patients with irritable bowel syndrome and dyspepsia: a prospective study | 17.2 | 0 | 1 |
| Vitamin B₁₂-containing plant food sources for vegetarians | 17.2 | 0 | 1 |
| A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome | 17.2 | 0 | 1 |
| Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial | 17.2 | 0 | 1 |
| Serum correlates of the placebo effect in irritable bowel syndrome | 17.2 | 0 | 1 |
| Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes | 17.2 | 0 | 1 |
| Clinical practice. Irritable bowel syndrome | 17.2 | 0 | 1 |
| Human gut microbiome viewed across age and geography | 17.2 | 0 | 1 |
| Nutritional supplements for age-related macular degeneration | 17.2 | 0 | 1 |
| Dietary fiber intake and mortality in the NIH-AARP diet and health study | 17.2 | 0 | 1 |
| Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial | 17.2 | 0 | 1 |
| Consumption of spicy foods and the prevalence of irritable bowel syndrome | 17.2 | 0 | 1 |
| Stronger is not always better: could a bodybuilding dietary supplement lead to ALS? | 17.2 | 0 | 1 |
| Probiotics and irritable bowel syndrome | 17.2 | 0 | 1 |
| Human nutrition, the gut microbiome and the immune system | 17.2 | 0 | 1 |
| Systematic review and meta-analysis of Saccharomyces boulardii in adult patients | 17.2 | 0 | 1 |
| Between celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivity | 17.2 | 0 | 1 |
| The Role of Stress on Physiologic Responses and Clinical Symptoms in Irritable Bowel Syndrome | 17.2 | 0 | 1 |
| The Environment Within: Exploring the Role of the Gut Microbiome in Health and Disease | 17.2 | 0 | 1 |
| The Dietary Supplement Protandim® Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular DystrophyMdxMice | 17.2 | 0 | 1 |
| An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome | 17.2 | 0 | 1 |
| Analgesic effect of Coptis chinensis rhizomes (Coptidis Rhizoma) extract on rat model of irritable bowel syndrome | 17.2 | 0 | 1 |
| Rapid Analytical Method for the Determination of Aflatoxins in Plant-Derived Dietary Supplement and Cosmetic Oils | 17.2 | 0 | 1 |
| Metagenomic analysis of the human distal gut microbiome | 17.2 | 0 | 1 |
| Probiotic therapy for irritable bowel syndrome | 17.2 | 0 | 1 |
| Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact | 17.2 | 0 | 1 |
| Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis | 17.2 | 0 | 1 |
| The differential diagnosis of food intolerance | 17.2 | 0 | 1 |
| Botanical dietary supplements gone bad | 17.2 | 0 | 1 |
| Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome | 17.2 | 0 | 1 |
| A core gut microbiome in obese and lean twins | 17.2 | 0 | 1 |
| STEMI in a 24-year-old man after use of a synephrine-containing dietary supplement: a case report and review of the literature | 17.2 | 0 | 1 |
| Complementary and alternative medicine for treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Determination of chondroitin sulfate content in raw materials and dietary supplements by high-performance liquid chromatography with ultraviolet detection after enzymatic hydrolysis: single-laboratory validation | 17.2 | 0 | 1 |
| Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation | 17.2 | 0 | 1 |
| Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome | 17.2 | 0 | 1 |
| Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis | 17.2 | 0 | 1 |
| Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States | 17.2 | 0 | 1 |
| Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential | 17.2 | 0 | 1 |
| Total folate and folic acid intake from foods and dietary supplements in the United States: 2003-2006 | 17.2 | 0 | 1 |
| Visceral hypersensitive rats share common dysbiosis features with irritable bowel syndrome patients | 17.2 | 0 | 1 |
| Irritable bowel syndrome | 17.2 | 0 | 1 |
| Assessing potential health risks from microcystin toxins in blue-green algae dietary supplements | 17.2 | 0 | 1 |
| CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome | 17.2 | 0 | 1 |
| A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing | 17.2 | 0 | 1 |
| Small intestinal bacterial overgrowth in patients with irritable bowel syndrome | 17.2 | 0 | 1 |
| Food intolerance and food allergy in children: a review of 68 cases | 17.2 | 0 | 1 |
| Genes and environment in irritable bowel syndrome: one step forward | 17.2 | 0 | 1 |
| How do SSRIs help patients with irritable bowel syndrome? | 17.2 | 0 | 1 |
| A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome | 17.2 | 0 | 1 |
| Systemic lactose intolerance: a new perspective on an old problem | 17.2 | 0 | 1 |
| Mycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicities | 17.2 | 0 | 1 |
| Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome | 17.2 | 0 | 1 |
| Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial | 17.2 | 0 | 1 |
| Partially responsive celiac disease resulting from small intestinal bacterial overgrowth and lactose intolerance | 17.2 | 0 | 1 |
| Assessment of a new synbiotic preparation in healthy volunteers: survival, persistence of probiotic strains and its effect on the indigenous flora | 17.2 | 0 | 1 |
| General practitioners believe that hypnotherapy could be a useful treatment for irritable bowel syndrome in primary care | 17.2 | 0 | 1 |
| Use of dietary supplements by female seniors in a large Northern California health plan | 17.2 | 0 | 1 |
| Dietary fiber showed no preventive effect against colon and rectal cancers in Japanese with low fat intake: an analysis from the results of nutrition surveys from 23 Japanese prefectures | 17.2 | 0 | 1 |
| Are herbal remedies and dietary supplements safe and effective for breast cancer patients? | 17.2 | 0 | 1 |
| Phytochemical Assays of Commercial Botanical Dietary Supplements | 17.2 | 0 | 1 |
| United European Gastroenterology | 17.2 | 0 | 1 |
| Occupational health of hired farmworkers in the United States. National agricultural workers survey occupational health supplement, 1999 | 17.2 | 0 | 1 |
| Template:WikiProject Dietary Supplements | 17.2 | 0 | 1 |
| Prevalence and work-relatedness of self-reported carpal tunnel syndrome (CTS) among U.S. workers - an analysis of 1988 National Health Interviews Survey, Occupational Health Supplement | 17.2 | 0 | 1 |
| Nutritional supplements for people being treated for active tuberculosis | 17.2 | 0 | 1 |
| Nutritional supplements for patients being treated for active visceral leishmaniasis | 17.2 | 0 | 1 |
| Oral nutritional supplements for treating venous leg ulcers | 17.2 | 0 | 1 |
| The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments | 17.2 | 0 | 1 |
| Dietary triggers in irritable bowel syndrome: Is there a role for gluten | 17.2 | 0 | 1 |
| Efficacy of Chinese Herbal Medicine for Diarrhea-Predominant Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials | 17.2 | 0 | 1 |
| Iron Fortification of Foods for Infants and Children in Low-Income Countries: Effects on the Gut Microbiome, Gut Inflammation, and Diarrhea | 17.2 | 0 | 1 |
| Effects of Physical Exercise Combined with Nutritional Supplements on Aging Brain Related Structures and Functions: A Systematic Review | 17.2 | 0 | 1 |
| Pancreatic Enzyme Supplements Are Not Effective for Relieving Abdominal Pain in Patients with Chronic Pancreatitis: Meta-Analysis and Systematic Review of Randomized Controlled Trials | 17.2 | 0 | 1 |
| Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome | 17.2 | 0 | 1 |
| The gut microbiome in human immunodeficiency virus infection | 17.2 | 0 | 1 |
| Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | 17.2 | 0 | 1 |
| Mechanism-Oriented Therapy of Irritable Bowel Syndrome | 17.2 | 0 | 1 |
| New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists | 17.2 | 0 | 1 |
| What goes around comes around: novel pharmacological targets in the gut-brain axis | 17.2 | 0 | 1 |
| Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics | 17.2 | 0 | 1 |
| Stem Cells in the Intestine: Possible Roles in Pathogenesis of Irritable Bowel Syndrome | 17.2 | 0 | 1 |
| Fatigue in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis of Pooled Frequency and Severity of Fatigue | 17.2 | 0 | 1 |
| Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment | 17.2 | 0 | 1 |
| Probiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders | 17.2 | 0 | 1 |
| Prevention and Conservative Therapy of Diverticular Disease | 17.2 | 0 | 1 |
| Fecal microbiota transplantation: in perspective | 17.2 | 0 | 1 |
| Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? | 17.2 | 0 | 1 |
| Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome | 17.2 | 0 | 1 |
| Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable | 17.2 | 0 | 1 |
| The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation | 17.2 | 0 | 1 |
| Gut Microbiome and Kidney Disease in Pediatrics: Does Connection Exist? | 17.2 | 0 | 1 |
| Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States | 17.2 | 0 | 1 |
| Inflammation in irritable bowel syndrome: Myth or new treatment target? | 17.2 | 0 | 1 |
| Gut microbiota role in irritable bowel syndrome: New therapeutic strategies | 17.2 | 0 | 1 |
| Th17 Cells in Type 1 Diabetes: Role in the Pathogenesis and Regulation by Gut Microbiome | 17.2 | 0 | 1 |
| Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside | 17.2 | 0 | 1 |
| THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review | 17.2 | 0 | 1 |
| Irritable bowel syndrome: Is it "irritable brain" or "irritable bowel"? | 17.2 | 0 | 1 |
| Effect of Nutrients, Dietary Supplements and Vitamins on Cognition: a Systematic Review and Meta-Analysis of Randomized Controlled Trials | 17.2 | 0 | 1 |
| Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances | 17.2 | 0 | 1 |
| Steering Endogenous Butyrate Production in the Intestinal Tract of Broilers as a Tool to Improve Gut Health | 17.2 | 0 | 1 |
| The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome | 17.2 | 0 | 1 |
| Short-term and Long-term Efficacy of Psychological Therapies for Irritable Bowel Syndrome: A Systematic Review and Meta-analysis | 17.2 | 0 | 1 |
| Lactose intolerance | 17.2 | 0 | 1 |
| Lactose intolerance in Indonesian children | 17.2 | 0 | 1 |
| Part 1: The Human Gut Microbiome in Health and Disease | 17.2 | 0 | 1 |
| Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance | 17.2 | 0 | 1 |
| The obese gut microbiome across the epidemiologic transition | 17.2 | 0 | 1 |
| Therapeutic Application of Synbiotics, a Fusion of Probiotics and Prebiotics, and Biogenics as a New Concept for Oral Candida Infections: A Mini Review | 17.2 | 0 | 1 |
| Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials | 17.2 | 0 | 1 |
| The Overlap between Irritable Bowel Syndrome and Non-Celiac Gluten Sensitivity: A Clinical Dilemma | 17.2 | 0 | 1 |
| Therapeutic Targets for Neurodevelopmental Disorders Emerging from Animal Models with Perinatal Immune Activation | 17.2 | 0 | 1 |
| Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. | 17.2 | 0 | 1 |
| Immunometabolism and the Kinome Peptide Array: A New Perspective and Tool for the Study of Gut Health | 17.2 | 0 | 1 |
| The Gut Microbiome and Its Potential Role in the Development and Function of Newborn Calf Gastrointestinal Tract | 17.2 | 0 | 1 |
| Psychosocial impact of irritable bowel syndrome: A brief review | 17.2 | 0 | 1 |
| Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders | 17.2 | 0 | 1 |
| Genetic epidemiology of irritable bowel syndrome | 17.2 | 0 | 1 |
| Aspects of the non-pharmacological treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Role of environmental pollution in irritable bowel syndrome | 17.2 | 0 | 1 |
| Irritable bowel syndrome and chronic constipation: Fact and fiction | 17.2 | 0 | 1 |
| Effects of Flavonoids from Food and Dietary Supplements on Glial and Glioblastoma Multiforme Cells | 17.2 | 0 | 1 |
| Role of creatine supplementation in exercise-induced muscle damage: A mini review | 17.2 | 0 | 1 |
| The Interrelationships between Lactose Intolerance and the Modern Dairy Industry: Global Perspectives in Evolutional and Historical Backgrounds | 17.2 | 0 | 1 |
| Liver Injury from Herbal, Dietary, and Weight Loss Supplements: a Review | 17.2 | 0 | 1 |
| Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases | 17.2 | 0 | 1 |
| Lactose Intolerance in Adults: Biological Mechanism and Dietary Management | 17.2 | 0 | 1 |
| The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome | 17.2 | 0 | 1 |
| The Diverse Forms of Lactose Intolerance and the Putative Linkage to Several Cancers | 17.2 | 0 | 1 |
| Clays as dietary supplements for swine: A review | 17.2 | 0 | 1 |
| The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective | 17.2 | 0 | 1 |
| Immunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature review | 17.2 | 0 | 1 |
| Xenobiotics: Interaction with the Intestinal Microflora | 17.2 | 0 | 1 |
| Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design | 17.2 | 0 | 1 |
| Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review | 17.2 | 0 | 1 |
| Nutritional Supplements in Support of Resistance Exercise to Counter Age-Related Sarcopenia | 17.2 | 0 | 1 |
| CODEX-aligned dietary fiber definitions help to bridge the ‘fiber gap’ | 17.2 | 0 | 1 |
| A Common Origin for Immunity and Digestion | 17.2 | 0 | 1 |
| Causes, symptoms and prevention of food allergy | 17.2 | 0 | 1 |
| Dietary Supplements and Hypertension: Potential Benefits and Precautions | 17.2 | 0 | 1 |
| Diagnosis of Irritable Bowel Syndrome: Role of Potential Biomarkers | 17.2 | 0 | 1 |
| Diet in irritable bowel syndrome | 17.2 | 0 | 1 |
| Health benefits of finger millet (Eleusine coracana L.) polyphenols and dietary fiber: a review | 17.2 | 0 | 1 |
| Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia | 17.2 | 0 | 1 |
| From 'lactose intolerance' to 'lactose nutrition' | 17.2 | 0 | 1 |
| Profile of rifaximin and its potential in the treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Neuropsychiatric Comorbidity in Obesity: Role of Inflammatory Processes | 17.2 | 0 | 1 |
| Alternative dietary fiber sources in companion animal nutrition | 17.2 | 0 | 1 |
| Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms | 17.2 | 0 | 1 |
| The three genetics (nuclear DNA, mitochondrial DNA, and gut microbiome) of longevity in humans considered as metaorganisms | 17.2 | 0 | 1 |
| What do we know about dietary fiber intake in children and health? The effects of fiber intake on constipation, obesity, and diabetes in children | 17.2 | 0 | 1 |
| Application of metagenomics in the human gut microbiome | 17.2 | 0 | 1 |
| Insect gut microbiome - An unexploited reserve for biotechnological application | 17.2 | 0 | 1 |
| Impact of psychological stress on irritable bowel syndrome | 17.2 | 0 | 1 |
| Intestinal Secretory Mechanisms in Irritable Bowel Syndrome–Diarrhea | 17.2 | 0 | 1 |
| Inside the trap: gland morphologies, digestive enzymes, and the evolution of plant carnivory in the Caryophyllales | 17.2 | 0 | 1 |
| Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome | 17.2 | 0 | 1 |
| Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndrome | 17.2 | 0 | 1 |
| Q26863305 | 17.2 | 0 | 1 |
| Ménage-à-trois of bariatric surgery, bile acids and the gut microbiome | 17.2 | 0 | 1 |
| Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide | 17.2 | 0 | 1 |
| Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis | 17.2 | 0 | 1 |
| Dietary supplements as a treatment for cervical cancer: a systematic review | 17.2 | 0 | 1 |
| The human gut microbiome and body metabolism: implications for obesity and diabetes | 17.2 | 0 | 1 |
| Irritable bowel syndrome: Relations with functional, mental, and somatoform disorders | 17.2 | 0 | 1 |
| Analysis of the Human Gut Microbiome and Association With Disease | 17.2 | 0 | 1 |
| Irritable bowel syndrome: A concise review of current treatment concepts | 17.2 | 0 | 1 |
| Estimating caffeine intake from energy drinks and dietary supplements in the United States | 17.2 | 0 | 1 |
| Towards predictive models of the human gut microbiome | 17.2 | 0 | 1 |
| Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver | 17.2 | 0 | 1 |
| Food Chain Mycotoxin Exposure, Gut Health, and Impaired Growth: A Conceptual Framework | 17.2 | 0 | 1 |
| Unraveling the ties between irritable bowel syndrome and intestinal microbiota | 17.2 | 0 | 1 |
| Post-infectious irritable bowel syndrome | 17.2 | 0 | 1 |
| Genetic polymorphism in pathogenesis of irritable bowel syndrome | 17.2 | 0 | 1 |
| Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome | 17.2 | 0 | 1 |
| Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways | 17.2 | 0 | 1 |
| Irritable Bowel Syndrome: A "Mesh" of a Situation | 17.2 | 0 | 1 |
| Irritable bowel syndrome | 17.2 | 0 | 1 |
| Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults | 17.2 | 0 | 1 |
| Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis | 17.2 | 0 | 1 |
| Medication Management of Irritable Bowel Syndrome | 17.2 | 0 | 1 |
| Physiological roles of dietary glutamate signaling via gut–brain axis due to efficient digestion and absorption | 17.2 | 0 | 1 |
| Brain–Gut Microbiome Interactions and Functional Bowel Disorders | 17.2 | 0 | 1 |
| The role of the gut microbiome in the pathogenesis and treatment of obesity | 17.2 | 0 | 1 |
| Update on Irritable Bowel Syndrome Program of Research | 17.2 | 0 | 1 |
| The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies | 17.2 | 0 | 1 |
| Canadian Digestive Health Foundation Public Impact Series 5: Pancreatitis in Canada. Incidence, prevalence, and direct and indirect economic impact | 17.2 | 0 | 1 |
| Diet and psoriasis, part III: role of nutritional supplements | 17.2 | 0 | 1 |
| The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D) | 17.2 | 0 | 1 |
| Review article: the aetiology, diagnosis, mechanisms and clinical evidence for food intolerance | 17.2 | 0 | 1 |
| Alcoholic Liver Disease: The Gut Microbiome and Liver Cross Talk | 17.2 | 0 | 1 |
| Melatonin for the treatment of irritable bowel syndrome | 17.2 | 0 | 1 |
| Dietary Fiber Future Directions: Integrating New Definitions and Findings to Inform Nutrition Research and Communication | 17.2 | 0 | 1 |
| The influence of lactose intolerance and other gastro-intestinal tract disorders on L-thyroxine absorption | 17.2 | 0 | 1 |
| Challenges in management of irritable bowel syndrome in children | 17.2 | 0 | 1 |
| Gluten Free | 17.2 | 0 | 1 |
| The effect of dietary supplementation with spent cider yeast on the Swine distal gut microbiome | 17.2 | 0 | 1 |
| Modification of Salmonella Typhimurium motility by the probiotic yeast strain Saccharomyces boulardii | 17.2 | 0 | 1 |
| Saccharomyces boulardii modifies Salmonella typhimurium traffic and host immune responses along the intestinal tract | 17.2 | 0 | 1 |
| Saccharomyces boulardii Improves Intestinal Epithelial Cell Restitution by Inhibiting αvβ5 Integrin Activation State | 17.2 | 0 | 1 |
| A bacterial filter protects and structures the gut microbiome of an insect. | 17.2 | 0 | 1 |
| Probiotic modulation of the microbiota-gut-brain axis and behaviour in zebrafish | 17.2 | 0 | 1 |
| Phylogenetic Characterization of Fecal Microbial Communities of Dogs Fed Diets with or without Supplemental Dietary Fiber Using 454 Pyrosequencing | 17.2 | 0 | 1 |
| Maternal Weaning Modulates Emotional Behavior and Regulates the Gut-Brain Axis. | 17.2 | 0 | 1 |
| Saccharomyces boulardii Improves Intestinal Cell Restitution through Activation of the α2β1 Integrin Collagen Receptor | 17.2 | 0 | 1 |
| Causality assessment in hepatotoxicity by drugs and dietary supplements | 17.2 | 0 | 1 |
| High frequency of lactose intolerance in a prehistoric hunter-gatherer population in northern Europe | 17.2 | 0 | 1 |
| Plant based dietary supplement increases urinary pH | 17.2 | 0 | 1 |
| Novel -glucosidase from human gut microbiome: substrate specificities and their switch | 17.2 | 0 | 1 |
| Bacteria of the human gut microbiome catabolize red seaweed glycans with carbohydrate-active enzyme updates from extrinsic microbes | 17.2 | 0 | 1 |
| Long-range Electrostatic Complementarity Governs Substrate Recognition by Human Chymotrypsin C, a Key Regulator of Digestive Enzyme Activation | 17.2 | 0 | 1 |
| Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review | 17.2 | 0 | 1 |
| Advanced technologies for the human gut microbiome analysis | 17.2 | 0 | 1 |
| Irritable bowel syndrome. | 17.2 | 0 | 1 |
| The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence | 17.2 | 0 | 1 |
| Suggested alternative starch utilization system from the human gut bacterium Bacteroides thetaiotaomicron | 17.2 | 0 | 1 |
| An obesity-associated gut microbiome with increased capacity for energy harvest | 17.2 | 0 | 1 |
| Expression of aquaporin 8 in colonic epithelium with diarrhoea-predominant irritable bowel syndrome. | 17.2 | 0 | 1 |
| Category:Food sensitivity | 17.2 | 0 | 1 |
| Psychological Interventions for Irritable Bowel Syndrome | 17.2 | 0 | 1 |
| Tiny microbes, enormous impacts: what matters in gut microbiome studies? | 17.2 | 0 | 1 |
| Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system | 17.2 | 0 | 1 |
| Diet and eczema: a review of dietary supplements for the treatment of atopic dermatitis | 17.2 | 0 | 1 |
| Clinical evaluation, biochemistry and genetic polymorphism analysis for the diagnosis of lactose intolerance in a population from northeastern Brazil | 17.2 | 0 | 1 |
| Combining pain therapy with lifestyle: the role of personalized nutrition and nutritional supplements according to the SIMPAR Feed Your Destiny approach | 17.2 | 0 | 1 |
| Managing irritable bowel syndrome: The low-FODMAP diet | 17.2 | 0 | 1 |
| Current Status of Translational Research on Irritable Bowel Syndrome | 17.2 | 0 | 1 |
| The Gut Microbiome as Therapeutic Target in Central Nervous System Diseases: Implications for Stroke | 17.2 | 0 | 1 |
| Biomarkers of Irritable Bowel Syndrome | 17.2 | 0 | 1 |
| Personality traits and emotional patterns in irritable bowel syndrome | 17.2 | 0 | 1 |
| Gut Microbiome and Infant Health: Brain-Gut-Microbiota Axis and Host Genetic Factors | 17.2 | 0 | 1 |
| Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome | 17.2 | 0 | 1 |
| Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place | 17.2 | 0 | 1 |
| Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome | 17.2 | 0 | 1 |
| Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Patient Version | 17.2 | 0 | 1 |
| Correlations of Host Genetics and Gut Microbiome Composition | 17.2 | 0 | 1 |
| Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Health Professional Version | 17.2 | 0 | 1 |
| Strain-level dissection of the contribution of the gut microbiome to human metabolic disease | 17.2 | 0 | 1 |
| Nerve growth factor and diarrhea-predominant irritable bowel syndrome (IBS-D): a potential therapeutic target? | 17.2 | 0 | 1 |
| Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis | 17.2 | 0 | 1 |
| Racial disparity in colorectal cancer: Gut microbiome and cancer stem cells | 17.2 | 0 | 1 |
| Logical hypothesis: Low FODMAP diet to prevent diverticulitis | 17.2 | 0 | 1 |
| Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome | 17.2 | 0 | 1 |
| Recent advances in Entamoeba biology: RNA interference, drug discovery, and gut microbiome | 17.2 | 0 | 1 |
| Metabolic modeling with Big Data and the gut microbiome | 17.2 | 0 | 1 |
| Digestive Enzyme Supplementation in Gastrointestinal Diseases | 17.2 | 0 | 1 |
| Irritable Bowel Syndrome: A Global Challenge Among Medical Students | 17.2 | 0 | 1 |
| β-hydroxy-β-methylbutyrate as a dietary supplement (II): cell and molecular mechanism of action | 17.2 | 0 | 1 |
| The Human Neonatal Gut Microbiome: A Brief Review | 17.2 | 0 | 1 |
| Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea | 17.2 | 0 | 1 |
| The role of the SCN 5A ‐encoded channelopathy in irritable bowel syndrome and other gastrointestinal disorders | 17.2 | 0 | 1 |
| Autochthonous microbiota, probiotics and prebiotics | 17.2 | 0 | 1 |
| Sarcopenia intervention with progressive resistance training and protein nutritional supplements | 17.2 | 0 | 1 |
| Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut | 17.2 | 0 | 1 |
| The interplay of the gut microbiome, bile acids, and volatile organic compounds | 17.2 | 0 | 1 |
| From next-generation sequencing to systematic modeling of the gut microbiome | 17.2 | 0 | 1 |
| Review article: gut‐directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease | 17.2 | 0 | 1 |
| The Infant Gut Microbiome: Evidence for Obesity Risk and Dietary Intervention | 17.2 | 0 | 1 |
| Gut Microbiota: Its Role in Hepatic Encephalopathy | 17.2 | 0 | 1 |
| Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis | 17.2 | 0 | 1 |
| Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial | 17.2 | 0 | 1 |
| Gut Microbiota as Potential Orchestrators of Irritable Bowel Syndrome | 17.2 | 0 | 1 |
| Immunomodulation of enteric neural function in irritable bowel syndrome | 17.2 | 0 | 1 |
| Gut Microbiome and Obesity: A Plausible Explanation for Obesity | 17.2 | 0 | 1 |
| Food allergy in irritable bowel syndrome: The case of non-celiac wheat sensitivity | 17.2 | 0 | 1 |
| Psychobiotics and the gut–brain axis: in the pursuit of happiness | 17.2 | 0 | 1 |
| Role of dietary polyphenols in the management of peptic ulcer | 17.2 | 0 | 1 |
| Diet, Gut Microbiome, and Bone Health | 17.2 | 0 | 1 |
| Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011 | 17.2 | 0 | 1 |
| Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU) | 17.2 | 0 | 1 |
| Effect of Saccharomyces boulardii on cAMP- and Ca2+ -dependent Cl- secretion in T84 cells | 17.2 | 0 | 1 |
| Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation, and intestinal adaptation after small-bowel resection in rats | 17.2 | 0 | 1 |
| Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii | 17.2 | 0 | 1 |
| Lactose intolerance | 17.2 | 0 | 1 |
| Irritable bowel syndrome in patients with Blastocystis hominis infection | 17.2 | 0 | 1 |
| Metabolic vitamin B12 status on a mostly raw vegan diet with follow-up using tablets, nutritional yeast, or probiotic supplements | 17.2 | 0 | 1 |
| Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus | 17.2 | 0 | 1 |
| Saccharomyces boulardii in maintenance treatment of Crohn's disease | 17.2 | 0 | 1 |
| Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania | 17.2 | 0 | 1 |
| Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia | 17.2 | 0 | 1 |
| Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial | 17.2 | 0 | 1 |
| A pilot trial of Saccharomyces boulardii in ulcerative colitis | 17.2 | 0 | 1 |
| An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents | 17.2 | 0 | 1 |
| Systematic review of herbs and dietary supplements for glycemic control in diabetes | 17.2 | 0 | 1 |
| Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome | 17.2 | 0 | 1 |
| Effects of dietary supplements on aspirin and other antiplatelet agents: an evidence-based approach | 17.2 | 0 | 1 |
| Dietary supplements in the setting of mohs surgery | 17.2 | 0 | 1 |
| Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial | 17.2 | 0 | 1 |
| The use of complementary/preventive medicine to prevent prostate cancer recurrence/progression following definitive therapy. Part II--rapid review of dietary supplements | 17.2 | 0 | 1 |
| Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children | 17.2 | 0 | 1 |
| Anaphylactic reaction to a dietary supplement containing willow bark | 17.2 | 0 | 1 |
| Review article: the complexity of drug development for irritable bowel syndrome | 17.2 | 0 | 1 |
| High-fat diets and cardiovascular disease: are nutritional supplements useful? | 17.2 | 0 | 1 |
| Role of dietary fiber and short-chain fatty acids in the colon | 17.2 | 0 | 1 |
| Sinapate dehydrodimers and sinapate-ferulate heterodimers in cereal dietary fiber | 17.2 | 0 | 1 |
| Inappropriate advertising of dietary supplements | 17.2 | 0 | 1 |